Chemoradiotherapy and Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

This clinical trial is focused on finding better treatment options for patients with limited-stage small cell lung cancer (SCLC). It explores the combination of chemotherapy and a dual immune therapy approach, which includes drugs that help the body's immune system fight cancer cells more effectively. The study also includes radiotherapy as part of the treatment. By testing this new combination, the researchers aim to determine how effective and safe it is, potentially offering new hope for improved outcomes in managing this type of lung cancer. Participants in the study will undergo a treatment plan that includes chemotherapy with etoposide and platinum-based drugs, paired with immune therapies known as PD-1 and CTLA-4 inhibitors, along with thymosin alpha 1. This treatment cycle is repeated four times. Additionally, radiation therapy to the chest is given early in the treatment process. For patients who show a positive response, preventive brain radiation might be suggested. After these steps, participants continue with immune therapy and thymosin alpha 1 as part of a year-long consolidation treatment, which helps to sustain the benefits of the initial therapy.